Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplastic Cells, Circulating × pertuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 141 HER2-positive Breast Cancer 15 Neoplasms 11 Neoplasm Metastasis 8 Carcinoma, Non-Small-Cell Lung 6 Prostatic Neoplasms 5 Ovarian Neoplasms 5 Stomach Neoplasms 4 Inflammatory Breast Neoplasms 4 Colonic Neoplasms 4 Brain Neoplasms 4 Triple Negative Breast Neoplasms 3 Solid Tumor 3 Pathologic Complete Response 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Endometrial Neoplasms 3 Breast Neoplasms, Male 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Rectal Neoplasms 2 Locally Advanced Breast Cancer 2 Hematologic Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 HER2-positive Early Breast Cancer 2 Gastrointestinal Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Ductal, Breast 2 Anatomic Stage II Breast Cancer AJCC v8 2

Interventions

Blood Specimen Collection 23 Surgical Procedures, Operative 4 Liquid Biopsy 4 cabazitaxel 3 Reverse Transcriptase Polymerase Chain Reaction 3 Propofol 3 Flow Cytometry 3 Bevacizumab 3 Trastuzumab 2 Spinal Puncture 2 Sevoflurane 2 Positron Emission Tomography Computed Tomography 2 Pirinitramide 2 Neoadjuvant Therapy 2 Morphine 2 Laparoscopy 2 Gemcitabine 2 Folfox protocol 2 Docetaxel 2 Cisplatin 2 Aspirin 2 Anesthesia, General 2 ribociclib 1 pertuzumab 1 osimertinib 1 lanreotide 1 jinfukang 1 eribulin 1 Watchful Waiting 1 Vinorelbine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04993014 2021-08-06

HER2Cell

AC Camargo Cancer Center

Phase 2 Recruiting

Breast Neoplasms, Neoplastic Cells, Circulating

Data powered by HemOnc (CC BY 4.0) Colophon ⚡